Home > Publications > Medical Specialty > Internal Medicine > Haematology > Myelofibrosis > Myelofibrosis Research Review, Issue 5
Myelofibrosis Research Review, Issue 5

Myelofibrosis Research Review, Issue 5

In this issue:

Tagraxofusp monotherapy has modest clinical activity
Encouraging anti-fibrotic activity for PXS-5505
Routine blood testing may aid in the diagnosis of pre-fibrotic myelofibrosis
European LeukemiaNet criteria for evaluation of new drugs
FIBROMET: metformin is a promising adjuvant therapy
Flonoltinib maleate outperforms ruxolitinib in Chinese trial
MANIFEST-2: Durable benefit to front-line pelabresib + ruxolitinib
Calreticulin-specific antibody promising for CALR mutated myelofibrosis
Nuvisertib + momelotinib for relapsed/ refractory myelofibrosis

You need to be logged in to access this content.

Jacinta-Perram

Expert contributor

Dr Jacinta Perram

Dr Jacinta Perram is a clinical, laboratory and transplant haematologist with an interest in myeloproliferative diseases. She has completed fellowships in transplant and CAR-T therapy and has extensive clinical research experience.

Latest Publications and Videos

Stay up to date with our latest clinical information.

Explore Research Review Publications and Videos

Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry. 

Find Reviews in Your Clinical Area
Please select your country of practice.

It looks like you are closest to our New Zealand site.

Terms and Conditions

Website terms of use 

By using our website, you agree to follow these terms and conditions. 

 

Privacy policy 

We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms. 

 

Copyright and use of website content 

The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use. 

You cannot:  copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission. 

 

Links to third-party websites 

The Research Review website may link to third-party websites for your convenience. However: 

We do not endorse or approve their products, services, or actions. 

We are not responsible for their content or how they operate. 

There is no formal partnership between us and third parties unless we clearly state otherwise. 

 

Disclaimer and limitation of liability 

We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date. 

To the fullest extent allowed by law, we are not responsible for: 

Any loss, damage, or costs you may suffer from using (or being unable to use) our website. 

Any decisions you make based on the information provided. 

Any business losses, such as lost profits, lost data, or business interruptions. 

 

Governing law 

These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.